Novo Nordisk A/S (NYSE:NVO) Shares Sold by Vantage Investment Partners LLC

Vantage Investment Partners LLC lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 19.8% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 428,797 shares of the company’s stock after selling 105,974 shares during the quarter. Novo Nordisk A/S comprises about 4.3% of Vantage Investment Partners LLC’s portfolio, making the stock its 5th largest holding. Vantage Investment Partners LLC’s holdings in Novo Nordisk A/S were worth $51,057,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its stake in Novo Nordisk A/S by 10.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,589,222 shares of the company’s stock worth $1,102,857,000 after purchasing an additional 823,036 shares in the last quarter. Envestnet Asset Management Inc. raised its stake in Novo Nordisk A/S by 1.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 4,254,180 shares of the company’s stock worth $607,242,000 after purchasing an additional 58,935 shares in the last quarter. GQG Partners LLC raised its stake in Novo Nordisk A/S by 654.6% in the 1st quarter. GQG Partners LLC now owns 3,633,064 shares of the company’s stock worth $466,485,000 after purchasing an additional 3,151,584 shares in the last quarter. Raymond James & Associates raised its stake in Novo Nordisk A/S by 1.0% in the 3rd quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock worth $419,939,000 after purchasing an additional 36,223 shares in the last quarter. Finally, 1832 Asset Management L.P. raised its stake in Novo Nordisk A/S by 7.8% in the 1st quarter. 1832 Asset Management L.P. now owns 2,373,029 shares of the company’s stock worth $304,697,000 after purchasing an additional 172,003 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on NVO shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Trading Up 1.8 %

Shares of Novo Nordisk A/S stock opened at $109.11 on Tuesday. The firm has a market capitalization of $489.63 billion, a PE ratio of 35.31, a price-to-earnings-growth ratio of 1.48 and a beta of 0.42. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm’s 50 day moving average is $121.42 and its 200 day moving average is $130.34. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.